Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.51 |
| ▸ | TNKS | O95271 | 7/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.48 |
| ▸ | PARG | Q86W56 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
| ▸ | TUBB | P07437 | 1/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7710641 | 0.89 | PARP14 (0.47) | ROCK2TNKSTNKS2PARGPARP1 | |
| SCHEMBL7716117 | 0.84 | ROCK2 (0.51) | ROCK2TNKSTNKS2PARGTUBB4A | |
| SCHEMBL7715493 | 0.83 | TNKS (0.44) | ROCK2TNKSTNKS2PARGPARP1 | |
| SCHEMBL31404576 | 0.82 | ROCK2 (0.46) | ROCK2TNKSTNKS2PARGTUBB4A | |
| SCHEMBL7716402 | 0.81 | KDM4E (0.58) | ROCK2PARGTUBB4ATUBBTUBA3C | |
| SCHEMBL16965438 | 0.80 | TNKS (0.72) | TNKSTNKS2PARP1KCNH2 | |
| SCHEMBL7713954 | 0.80 | PARP1 (0.54) | ROCK2TNKSTNKS2PARP1CDC7 | |
| SCHEMBL30496105 | 0.80 | PARP1 (0.54) | ROCK2TNKSTNKS2PARP1CDC7 | |
| SCHEMBL2708884 | 0.80 | MPO (0.54) | PARP1KCNH2MAPK13RAF1MAPK9 | |
| SCHEMBL31404562 | 0.80 | TUBB4A (0.45) | ROCK2TNKSTNKS2PARGTUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376500-B2 | 1-(INDOL-3-YLALKYL)ALKYLPIPERIDIN-4 -YL)-3H-QUINOLIN-4-ONE, FOR EXAMPLE; ALPHA1A/ B-RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION; UROGENITAL DISORDERS; BENIGN PROSTATIC HYPERTROPHY; ANALGESICS FOR INFLAMMATORY, NEUROPATHY, CANCER, | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-20010051627-A1 | Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)- 4(3H)-azaquinazolinones | CLARK ROBIN DOUGLAS (US) | 2001-12-13 | — | — | US | disclosed |
| US-6258819-B1 | BIOLOGICAL RECEPTORS, ANTIINFLAMMATORY AGENTS, BENIGN PROSTATE AND SIDE EFFECT REDUCTION | SYNTEX (U.S.A.) LLC | 2001-07-10 | — | — | US | disclosed |
| WO-2001010860-A2 | QUINAZOLINONE AND AZAQUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051627-A1 | Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)- 4(3H)-azaquinazolinones | ADRA2B, ADRA1D, ADRA1B | ROCK2 3023/4885TNKS 1559/4885TNKS2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.